Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus

Int J Hematol. 2014 Aug;100(2):188-99. doi: 10.1007/s12185-014-1613-z. Epub 2014 Jul 1.

Abstract

The present study was conducted to investigate Epstein-Barr virus (EBV) reactivation after hematopoietic cell transplantation (HCT) in Korean children living in an area of a high seroprevalence against EBV and to determine the impact of recipient age on EBV reactivation. Medical records of 248 children and adolescents who had received allogeneic HCT were retrospectively reviewed. The trends of EBV reactivation and post-transplant lymphoproliferative disorders (PTLDs) were evaluated and compared between younger (≤10 years old) and older (11-20 years old) groups. EBV reactivation occurred in 177 cases (71.4 %) and high-level EBV reactivation, defined as a virus DNA titer of 300,000 copies/mL or higher, occurred in 21 cases (8.5 %). PTLD was diagnosed in five cases (2.0 %), and one of these patients died. The EBV reactivation rate was not significantly different between the two age groups; however, high-level reactivation and PTLD were more significantly frequent in the older than in the younger group (P = 0.030 and P = 0.026, respectively). In conclusion, older children and adolescents are more likely to experience high-level EBV reactivation and PTLDs, and higher EBV DNA titers than those previously reported may be a predictor of PTLD in areas with a high seroprevalence against EBV.

MeSH terms

  • Adolescent
  • Antibodies, Viral / blood*
  • Antineoplastic Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Epstein-Barr Virus Infections / etiology
  • Epstein-Barr Virus Infections / pathology*
  • Epstein-Barr Virus Infections / virology
  • Female
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / pathology
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Herpesvirus 4, Human / pathogenicity
  • Herpesvirus 4, Human / physiology*
  • Humans
  • Infant
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / pathology*
  • Lymphoproliferative Disorders / virology
  • Male
  • Remission Induction
  • Republic of Korea
  • Retrospective Studies
  • Seroepidemiologic Studies
  • Transplantation, Homologous
  • Treatment Outcome
  • Viral Load
  • Virus Activation
  • Young Adult

Substances

  • Antibodies, Viral
  • Antineoplastic Agents